{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:28:31Z","timestamp":1794360511365,"version":"4.9.0"},"reference-count":161,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/14740338.2024.2447072","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T09:56:51Z","timestamp":1735120611000},"page":"395-411","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?"],"prefix":"10.1080","volume":"24","author":[{"given":"Annie","family":"Tang","sequence":"first","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0631-3"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23528"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c140048"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr291"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2007.07.005"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-022-02996-8"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.5435\/00124635-200203000-00009"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.04.005"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e3181e9a34b"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.03.011"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-230220"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.573666"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S93873"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/DBP.0000000000001105"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1180"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.305065"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12914"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(03)00048-0"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200204076"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1996.tb00781.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv154"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(92)90004-P"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12735"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-081117-010451"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2014.274878"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004840117"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12981-5"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00585-4"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008803"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271681"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175637"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz049"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(02)00088-3"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl083"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(01)00220-6"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/11.26.3333"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.12.2103052"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002337"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2150543"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1868434"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7374-3_10"},{"key":"e_1_3_4_50_1","volume-title":"Data from international public\/private partnership leads to the first therapy for Duchenne muscular dystrophy approved by both EMA and FDA","author":"ReveraGen BioPharma Inc","year":"2023","unstructured":"ReveraGen BioPharma Inc. Data from international public\/private partnership leads to the first therapy for Duchenne muscular dystrophy approved by both EMA and FDA. Rockfield, MD: ReveraGen BioPharma Inc; 2023. https:\/\/reveragen.com\/wp-content\/uploads\/22-December-2023-ReveraGen-press-release-final.pdf"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0205-4"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041307"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01845-0"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01902-8"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01788-y"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010511"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01162-5"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.194"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01929-x"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101147"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03304-z"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800149-3.00003-2"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50569-6"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2016.001"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/343180a0"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210678"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.01.002"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098174"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07710-8"},{"key":"e_1_3_4_72_1","doi-asserted-by":"crossref","unstructured":"Kodippili K Duan D. Expressing full-length Dystrophin using Adeno-associated virus. Gene therapy in neurological disorders. Elsevier. 2018. p. 259\u2013276.","DOI":"10.1016\/B978-0-12-809813-4.00013-2"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411421"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.07.021"},{"key":"e_1_3_4_75_1","doi-asserted-by":"crossref","unstructured":"Laugel V De Luca S Davion J et al. BORDEAUXGNT0004 Genethon\u2019s AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy first data of the phase I\/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys. Myology 2024. Paris: Myology 2024 Abstracts; 2024.","DOI":"10.1016\/j.nmd.2024.07.290"},{"key":"e_1_3_4_76_1","unstructured":"Sarepta Therapeutics. Sarepta therapeutics announces topline results from EMBARK a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. 2023 Oct 30 [cited 2024 Aug 12]. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-topline-results-embark-global-0"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165869"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805263182104"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1011"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84863-w"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306350"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_3_4_83_1","unstructured":"Sarepta. Sarepta therapeutics announces expanded US FDA approval of ELEVIDYS to Duchenne muscular dystrophy patients ages 4 and above 6\/20\/24-FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients-fda grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients Available from: https:\/\/investorrelations.sarepta.com\/events-"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15900"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2216518"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762"},{"key":"e_1_3_4_87_1","article-title":"FDA sets date for full approval, broader indication for Elevidys","author":"Myshko D","year":"2024","unstructured":"Myshko D. FDA sets date for full approval, broader indication for Elevidys. Formulary Watch. 2024 Feb 14. https:\/\/www.managedhealthcareexecutive.com\/view\/fda-sets-date-for-full-approval-broader-indication-for-elevidys","journal-title":"Formulary Watch"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.240335297"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.29198.bfs"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.29211.bfs"},{"key":"e_1_3_4_91_1","article-title":"Patient death reported in phase 2 DAYLIGHT study of Pfizer\u2019s gene therapy for duchenne","author":"Meglio M","year":"2024","unstructured":"Meglio M. Patient death reported in phase 2 DAYLIGHT study of Pfizer\u2019s gene therapy for duchenne. Neurol Live. 2024 May 8. https:\/\/www.neurologylive.com\/view\/patient-death-reported-phase-2-daylight-study-pfizer-gene-therapy-duchenne","journal-title":"Neurol Live"},{"key":"e_1_3_4_92_1","unstructured":"Pfizer. Pfizer provides update on phase 3 study of investigational gene therapy for ambulatory boys with Duchenne muscular dystrophy [Internet]. 2024. Available from: www.Pfizer.com"},{"key":"e_1_3_4_93_1","article-title":"Solid biosciences receives FDA fast track designation for Duchenne muscular dystrophy gene therapy SGT-003","author":"Solid Biosciences","year":"2023","unstructured":"Solid Biosciences. Solid biosciences receives FDA fast track designation for Duchenne muscular dystrophy gene therapy SGT-003. Solid Biosci. 2023. https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-receives-fda-fast-track-designation-duchenne#:~:text=(Nasdaq%3A%20SLDB)%2C%20a,Duchenne%20muscular%20dystrophy%20(Duchenne)%20gene","journal-title":"Solid Biosci"},{"key":"e_1_3_4_94_1","volume-title":"2024 MDA Clinical and Scientific Conference","author":"Salabarria S","year":"2024","unstructured":"Salabarria S, Shih R, Leon C, et al. Evaluation of long-term cardiac MRI outcome following micro-dystrophin gene therapy in subjects with Duchenne muscular dystrophy receiving SGT-001. In: 2024 MDA Clinical and Scientific Conference; Orlando (FL). 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; 2024."},{"key":"e_1_3_4_95_1","article-title":"Solid biosciences reports Fourth Quarter and full-year 2021 financial results and 2-year efficacy and safety data from the ongoing phase I\/II IGNITE DMD clinical trial of SGT-001","author":"Solid Biosciences","year":"2022","unstructured":"Solid Biosciences. Solid biosciences reports Fourth Quarter and full-year 2021 financial results and 2-year efficacy and safety data from the ongoing phase I\/II IGNITE DMD clinical trial of SGT-001. Solid Biosci. 2022. https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-reports-fourth-quarter-and-full-year-2021","journal-title":"Solid Biosci"},{"key":"e_1_3_4_96_1","unstructured":"Solid Biosciences. Solid biosciences announces acquisition of AavantiBio and concurrent $75 million Private placement [internet]. Solid biosciences. 2022 [cited 2024 Aug 25]. Available from: https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-acquisition-of-aavantibio-and-concurrent-75-million-private-placement"},{"key":"e_1_3_4_97_1","unstructured":"Genethon. Genethon announces first patient dosed in clinical trial of investigational gene therapy GNT 0004 for Duchenne muscular dystrophy [internet]. Genethon. 2021 [cited 2023 Oct 21]. Available from: https:\/\/www.genethon.com\/genethon-announces-first-patient-dosed-in-clinical-trial-of-investigational-gene-therapy-gnt-0004-for-duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_98_1","unstructured":"Rengenxbio. Regenxbio announces new positive initial efficacy data from affinity duchenne\u00ae trial. 2024."},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/6981"},{"key":"e_1_3_4_100_1","unstructured":"Genethon. Duchenne Muscular Dystrophy - Our Pipeline [Internet]. Genethon. 2023 [cited 2023 Oct 21]. Available from: https:\/\/www.genethon.com\/our-pipeline\/duchenne-muscular-dystrophy\/"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12121979"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174098"},{"key":"e_1_3_4_103_1","unstructured":"Muntoni F. First clinical trial results of gene therapy (GNT0004) for Duchenne muscular dystrophy presented at international myology 2024 congress. International Myology 2024 Congress. Genethon; 2024."},{"key":"e_1_3_4_104_1","article-title":"A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD","author":"Bonnemann CG","year":"2022","unstructured":"Bonnemann CG, Belluscio BA, Braun S, et al. A collaborative analysis by clinical trial sponsors and academic experts of anti-transgene SAEs in studies of gene therapy for DMD. Mol Ther. 2022. https:\/\/www.mdaconference.org\/abstract-library\/a-collaborative-analysis-by-clinical-trial-sponsors-and-academic-experts-of-anti-transgene-saes-in-studies-of-gene-therapy-for-dmd\/","journal-title":"Mol Ther"},{"key":"e_1_3_4_105_1","article-title":"Sarepta and two others suggest Duchenne drug safety issues tied to \u201cclass effect\u201d","author":"Pfizer GM","year":"2022","unstructured":"Pfizer GM. Sarepta and two others suggest Duchenne drug safety issues tied to \u201cclass effect\u201d. Endpoints News. 2022 May 18. https:\/\/endpts.com\/pfizer-sarepta-and-two-others-suggest-duchenne-drug-safety-issues-may-have-class-effect\/","journal-title":"Endpoints News"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2212912"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.01.003"},{"key":"e_1_3_4_108_1","unstructured":"Goedeker NL Aqul AA Butterfield RJ et al. Management of patients following investigational delandistrogene moxeparvovec gene therapy for Duchenne muscular dystrophy: delphi panel consensus considerations based on clinical trial experience acknowledgments and disclosures acknowledgments [Internet]. 2023. Available from: https:\/\/www.ismpp.org\/gpp-"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173510"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803"},{"key":"e_1_3_4_111_1","first-page":"77","volume-title":"MDA Clinical and Scientific Conference 2021","author":"Belluscio B","year":"2021","unstructured":"Belluscio B, Beaverson K, Garnier N, et al. Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1b study. In: MDA Clinical and Scientific Conference 2021; 2021. p. 77. Available from cited 2023 Aug 12]. Available from: https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study\/"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307798"},{"key":"e_1_3_4_113_1","article-title":"DMD gene therapy death exposes risks of treating older patients","author":"Taylor NP","year":"2023","unstructured":"Taylor NP. DMD gene therapy death exposes risks of treating older patients. Fierce Biotech. 2023 May 19. https:\/\/www.fiercebiotech.com\/biotech\/dmd-gene-therapy-death-exposes-risks-treating-older-patients","journal-title":"Fierce Biotech"},{"key":"e_1_3_4_114_1","unstructured":"REGENXBIO. Therapeutic pipeline: RGX-202 for duchenne. REGENXBIO [Internet]. 2023 [cited 2023 Aug 12]. Available from: https:\/\/www.regenxbio.com\/therapeutic-programs\/rgx-202\/"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00154.2021"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03041-4"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.217"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI177078"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep07581"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031832"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232033"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genet-071719-022559"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2018.1493331"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122003"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/384349a0"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2600"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2016.11.004"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102247"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4324"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau1549"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.10.004"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1254445"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.07.024"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.05.014"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.03.005"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169176"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052898"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddv120"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0738-2"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1534-x"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1580"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.09.003"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26714-w"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244215"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0344-3"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.03.004"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.6b00226"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20153719"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.07.004"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26830-7"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309915"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000083"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.7936"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301066"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405972101"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087057112465648"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1503-1"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2019.130819"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2020.08.031"},{"key":"e_1_3_4_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.11.012"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2024.2313105"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040038"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.01.016"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2024.2447072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T18:50:24Z","timestamp":1743533424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2024.2447072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/14740338.2024.2447072"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2024.2447072","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}